Infusional β-lactam antibiotics in febrile neutropenia: Has the time come?

Current Opinion in Infectious Diseases

Volumn 25, Issue 6, 2012, Pages 619-625

  Abbott, Iain J ^a   Roberts, Jason A ^b,c  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

antibiotic; carbapenem; cephalosporin; continuous infusion; extended infusion; penicillin; pharmacodynamics; pharmacokinetics; resistance

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFOZOPRAN; CEFTAZIDIME; IMIPENEM; MEROPENEM; PIPERACILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CONTINUOUS INFUSION; CRITICAL ILLNESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; FEBRILE NEUTROPENIA; HUMAN; LOADING DRUG DOSE; PATHOPHYSIOLOGY; REVIEW;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMS; FEVER OF UNKNOWN ORIGIN; HUMANS; INFUSIONS, INTRAVENOUS; NEUTROPENIA; TREATMENT OUTCOME;

EID: 84870062705     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835915c2     Document Type: Review

References (62)

1. Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis 2011; 53:798-806.
2. de Naurois J, Novitzky-Basso I, Gill MJ, et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2010; 21 (SUPPL. 5):v252-v256.
3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52:427-431.
4. Lingaratnam S, Slavin MA, Koczwara B, et al. Introduction to the Australian consensus guidelines for the management of neutropenic fever in adult cancer patients, 2010/2011. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41:75-81.
5. Tam CS, O'Reilly M, Andresen D, et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41:90-101.
6. Legrand M, Max A, Peigne V, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 2012; 40:43-49.
7. Thirumala R, Ramaswamy M, Chawla S. Diagnosis and management of infectious complications in critically ill patients with cancer. Crit Care Clin 2010; 26:59-91.
8. Theuretzbacher U. Pharmacokinetic and pharmacodynamic issues for antimicrobial therapy in patients with cancer. Clin Infect Dis 2012; 54:1785-1792. An important review detailing the pharmacokinetic/pharmacodynamic issues seen specifically in the immunocompromised host with cancer. It raises important and practical considerations for optimizing antibiotic exposure is this patient group.
9. Spellberg B, Blaser M, Guidos RJ, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 2011; 52 (SUPPL. 5): S397-S428.
10. Mouton JW, Ambrose PG, Canton R, et al. Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective. Drug Resist Updat 2011; 14:107-117.
11. Falagas ME, Karageorgopoulos DE. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 2010; 375:248-251.
12. McKenzie C. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011; 66 (SUPPL. 2):ii25-ii31.
13. Lodise TP, Drusano GL. Pharmacokinetics and pharmacodynamics: optimal antimicrobial therapy in the intensive care unit. Crit Care Clin 2011; 27:1-18.
14. Levison ME, Levison JH. Pharmacokinetics and pharmacodynamics of antibacterial agents. Infect Dis Clin North Am 2009; 23:791-815; vii.
15. Mouton JW, Punt N, Vinks AA. Concentration-effect relationship of ceftazidime explains why the time above the MIC is 40 percentage for a static effect in vivo. Antimicrob Agents Chemother 2007; 51:3449-3451. (Pubitemid 350067577)
16. Lortholary O, Lefort A, Tod M, et al. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. Lancet Infect Dis 2008; 8:612-620.
17. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2:289-300. (Pubitemid 39490099)
18. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilising pharmacodynamic principles: impact on the development of resistance. Drugs 2006; 66:1-14. (Pubitemid 43144960)
19. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44:79-86. (Pubitemid 44968990)
20. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing betalactam therapy. Crit Care Clin 2011; 27:77-93.
21. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13:598-606. (Pubitemid 47357464)
22. Navas D, Caillon J, Batard E, et al. Trough serum concentrations of betalactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams. Int J Antimicrob Agents 2006; 27:102-107. (Pubitemid 43138841)
23. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37:2071-2078.
24. Geli P, Laxminarayan R, Dunne M, Smith DL. One-size-fits-all'? Optimizing treatment duration for bacterial infections. PLoS One 2012; 7:e29838. Mathematical modeling demonstrating the importance of the intact immune system and the ecological dynamics of infecting bacteria and the selection of resistant subpopulations.
25. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011; 15:R206. A thorough review of the pharmacokinetics of b-lactams in critically ill patients.
26. Pea F, Viale P, Damiani D, et al. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob Agents Chemother 2005; 49:3550-3553. (Pubitemid 41060617)
27. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Scand J Infect Dis 2001; 33:222-226. (Pubitemid 32258033)
28. Daenen S, Erjavec Z, Uges DR, et al. Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. Eur J Clin Microbiol Infect Dis 1995; 14:188-192.
29. Nomura K, Morikawa N, Ikawa K, et al. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 2008; 61:892-900. (Pubitemid 351426076)
30. Ohata Y, Tomita Y, Nakayama M, et al. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic-pharmacodynamic analysis. J Infect Chemother 2011; 17:831-841.
31. Jaruratanasirikul S, Limapichat T, Jullangkoon M, et al. Pharmacodynamics of meropenem in critically ill patients with febrile neutropenia and bacteraemia. Int J Antimicrob Agents 2011; 38:231-236.
32. Lee DG, Choi SM, Shin WS, et al. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 2006; 28:333-339.
33. Ariano RE, Nyhlen A, Donnelly JP, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005; 39:32-38. (Pubitemid 40052375)
34. Nyhlen A, Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group. Eur J Clin Microbiol Infect Dis 1997; 16:797-802. (Pubitemid 27527056)
35. Lamoth F, Buclin T, Csajka C, et al. Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies. Antimicrob Agents Chemother 2009; 53:785-787.
36. Janmohamed RM, Leyland MJ, Kelly J, Farrell I. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1990; 25:407-412. (Pubitemid 20127007)
37. Drusano GL, Plaisance KI, Forrest A, et al. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother 1987; 31:1420-1422. (Pubitemid 17148313)
38. Drusano GL, Forrest A, Plaisance KI, Wade JC. A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients. Clin Pharmacol Ther 1989; 45:635-641. (Pubitemid 19184175)
39. Taccone FS, Laterre PF, Dugernier T, et al. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14:R126.
40. Seyler L, Cotton F, Taccone FS, et al. Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15:R137.
41. El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer. Pediatr Blood Cancer 2011; 57:283-288.
42. Gudiol C, Tubau F, Calatayud L, et al. Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 2011; 66:657-663.
43. Tadesse DA, Zhao S, Tong E, et al. Antimicrobial drug resistance in Escherichia coli from humans and food animals, United States, 1950-2002. Emerg Infect Dis 2012; 18:741-749.
44. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30:355-360.
45. van Hees BC, Tersmette M, Willems RJ, et al. Molecular analysis of ciprofloxacin resistance and clonal relatedness of clinical Escherichia coli isolates from haematology patients receiving ciprofloxacin prophylaxis. J Antimicrob Chemother 2011; 66:1739-1744.
46. Bow EJ. Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 2011; 24:545-553.
47. Slavin MA, Lingaratnam S, Mileshkin L, et al. Use of antibacterial prophylaxis for patients with neutropenia. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011; 41:102-109.
48. Olofsson SK, Cars O. Optimizing drug exposure to minimize selection of antibiotic resistance. Clin Infect Dis 2007; 45 (SUPPL. 2):S129-S136. (Pubitemid 47328627)
49. zur Wiesch PA, Kouyos R, Engelstadter J, et al. Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect Dis 2011; 11:236-247. An interesting review detailing the principles of drug resistance.
50. Goessens WH, Mouton JW, ten Kate MT, et al. Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J Antimicrob Chemother 2007; 59:507-516. (Pubitemid 47073458)
51. Bakker-Woudenberg IA, ten Kate MT, Goessens WH, Mouton JW. Effect of treatment duration on pharmacokinetic/pharmacodynamic indices correlating with therapeutic efficacy of ceftazidime in experimental Klebsiella pneumoniae lung infection. Antimicrob Agents Chemother 2006; 50:2919-2925. (Pubitemid 44396393)
52. Lodise TP Jr., Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357-363. (Pubitemid 46147617)
53. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of piperacillintazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacotherapy 2007; 27:1490-1497. (Pubitemid 350060204)
54. Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis: bolus versus continuous administration? Crit Care Med 2009; 37:926-933.
55. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics -insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320-1332. (Pubitemid 44306892)
56. Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009; 53: 1476-1481.
57. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006; 46:1171-1178. (Pubitemid 44387417)
58. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64:142-150.
59. Berthoin K, Le Duff CS, Marchand-Brynaert J, et al. Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 2010; 65:1073-1075.
60. Roberts JA, Kirkpatrick CM, Roberts MS, et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 2010; 35:156-163.
61. Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65:1771-1778.
62. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010; 36:332-339.